The U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $397,824 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to ELI (Elsohly Laboratories, Incorporated), doing business as E L I. The funding supports the isolation and pharmacological evaluation of impurities in synthetic D-8-THC products. Specifically, the project aims to: 1) scale up the isolation process for impurities in D-8-THC products to obtain sufficient supply for in vitro and in vivo testing; 2) assess the binding affinity, potency, and behavioral effects of these impurities using receptor binding assays, functional assays, and animal studies; and 3) determine if the impurities can potentiate, antagonize, or have additive effects with D-8-THC. This research will provide valuable insights into the pharmacology of D-8-THC impurities and their influence on the psychoactive effects of this synthetic cannabinoid. The award period runs from April 15, 2024, to March 31, 2026.
Generated 1/28/25, 8:50 AM